- Home
- TARA vs IKT Comparison
TARA vs IKT Comparison
Compare TARA & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | IKT |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 240.1M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TARA | IKT |
|---|---|---|
| Price | $5.17 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $23.60 | $5.00 |
| AVG Volume (30 Days) | 523.4K | ★ 1.0M |
| Earning Date | 05-01-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.25 | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $1.33 |
| 52 Week High | $7.82 | $2.37 |
Technical Indicators
Market Signals| Indicator | TARA | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 54.96 |
| Support Level | $4.92 | $1.43 |
| Resistance Level | $5.44 | $1.88 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 41.54 | 75.00 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.